Skf 107457

Summary

SKF 107457 is a synthetic hexapeptide analogue designed to inhibit the HIV‑1 protease enzyme. In the described study it was examined as a hydroxyethylene‑based inhibitor, where the scissile peptide bond is replaced by a non‑cleavable hydroxyethylene isostere. The compound was investigated primarily through X‑ray crystallography to understand how it binds the protease, rather than through clinical or pharmacological testing.

Mechanism of Action

SKF 107457 mimics the natural substrate of HIV‑1 protease but contains a hydroxyethylene group that cannot be cleaved. By occupying the enzyme’s active‑site cleft, the inhibitor forms van der Waals contacts with surrounding residues, preventing the protease from processing viral polyproteins. This blockade halts the maturation of infectious HIV particles, a mechanism shared by other protease‑targeting agents, though the specific binding orientation of SKF 107457 was shown to adopt two equally populated conformations in crystal form.

What the Research Shows

A 1992 structural biology study reported the 2.2‑Å resolution crystal structures of HIV‑1 protease bound to SKF 107457 (and a related compound, SKF 108738). Both inhibitors are hexapeptide substrate analogues in which the peptide bond is replaced by a hydroxyethylene isostere. The structures revealed that, unlike earlier inhibitor‑enzyme complexes, the inhibitors were observed in two distinct, equally abundant orientations within the homodimeric protease. Differences in van der Waals interactions were noted throughout the complexes, despite only minor variations at the P1′ site of the inhibitors. These findings provided detailed insight into how hydroxyethylene‑based inhibitors engage the protease active site.

Reported Benefits

The primary benefit demonstrated by the study is the provision of high‑resolution structural data on how a hydroxyethylene‑based peptide inhibitor binds HIV‑1 protease. Such information can guide rational design of more potent protease inhibitors by highlighting key interactions and the flexibility of binding orientations, potentially accelerating the development of antiviral agents.

Limitations of the Evidence

Evidence for SKF 107457 is limited to a single crystallographic report; no biochemical activity, pharmacokinetic, toxicity, or clinical data are presented. The study does not assess antiviral efficacy, dosing, or safety, and the compound’s regulatory status remains unknown. Consequently, conclusions about therapeutic potential are speculative and require extensive further investigation.

Safety Considerations

The abstract provides no information on adverse effects, toxicity, or tolerability of SKF 107457. Without preclinical or clinical safety data, no conclusions can be drawn about its safety profile. Any use of the compound outside of research settings would be unsupported by the available literature.

How It Is Administered

No formulation, route of administration, or dosing details are reported for SKF 107457. The compound has only been described in the context of in‑vitro crystallographic studies, and no information on how it might be delivered in a therapeutic context is available.

Routes of Administration

No administration routes recorded yet.

Goals & Uses

No goal associations recorded yet.

Contraindications

No contraindications recorded yet.

Adverse Effects

No adverse effects recorded yet.

Drug Interactions

No drug interactions recorded yet.

Population Constraints

No population constraints recorded yet.

Regulatory Status

No regulatory status recorded yet.

Evidence & Sources

• The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations
  Journal ArticleLowMurthy KH, et al.1992-01-01T00:00:00.000000Z

Frequently Asked Questions